DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
12h
The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
With meteorologists forecasting a polar vortex with severe cold temperatures dropping to as low as -23°F across many states, battery charging expert CTEK warns that up to 50% of drivers could face ...
The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP's Annual MLK Jr.
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
UK pharma major AstraZeneca on Friday revealed that Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the ...
This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback